Published in Sex Transm Infect on October 01, 1999
Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med (1998) 3.14
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. J Virol Methods (1993) 2.24
Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS (1998) 1.59
Factors associated with increased levels of human immunodeficiency virus type 1 DNA in semen. J Infect Dis (1997) 1.21
Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA (1988) 1.15
Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science (1998) 19.40
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol (1998) 5.48
Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis (1999) 4.67
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66
Rotavirus serotypes by serum neutralisation. J Med Virol (1980) 3.65
Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis (2000) 3.63
Sequential coupling between COPII and COPI vesicle coats in endoplasmic reticulum to Golgi transport. J Cell Biol (1995) 3.57
The organization of endoplasmic reticulum export complexes. J Cell Biol (1996) 3.32
Staging system for clinical AIDS patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Lancet (1995) 2.90
1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet (1998) 2.82
Sar1 promotes vesicle budding from the endoplasmic reticulum but not Golgi compartments. J Cell Biol (1994) 2.75
Shedding light on the sexual history. Am J Nurs (1999) 2.56
Serotyping and subgrouping of rotavirus strains by the ELISA test. Arch Virol (1982) 2.49
Brief report: infection of a laboratory worker with simian immunodeficiency virus. N Engl J Med (1994) 2.32
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med (2007) 2.19
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
Hepatitis C virus infection and liver disease in blood donors. Br J Hosp Med (1994) 2.04
Enzyme-linked immunosorbent assays based on polyclonal and monoclonal antibodies for rotavirus detection. J Clin Microbiol (1984) 2.03
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med (2003) 1.94
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut (2004) 1.93
Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res (1984) 1.88
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS (2001) 1.86
Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res (1988) 1.84
Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. J Clin Microbiol (1993) 1.83
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med (1997) 1.80
Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis (1998) 1.77
Development and evaluation of a PCR-based immunoassay for the rapid detection of methicillin-resistant Staphylococcus aureus. J Med Microbiol (1998) 1.76
TT virus infection in patients with hepatitis C: frequency, persistence, and sequence heterogeneity. J Infect Dis (1999) 1.76
Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol (2001) 1.75
Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol (2001) 1.74
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med (2006) 1.73
Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr (1985) 1.73
An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. J Immunol (1991) 1.70
Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci U S A (1988) 1.69
Implications for HIV testing policy derived from combining data on voluntary confidential testing with viral sequences and serological analyses. Sex Transm Infect (2008) 1.66
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS (1999) 1.65
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother (2005) 1.63
Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat (2009) 1.63
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis (2001) 1.62
Rotavirus epidemiology in Vellore, south India: group, subgroup, serotype, and electrophoretype. J Clin Microbiol (1988) 1.60
Polymorphism of genomic RNAs within rotavirus serotypes and subgroups. Arch Virol (1982) 1.58
Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS (1992) 1.56
Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med (2001) 1.55
Subgroups, serotypes, and electrophoretypes of rotavirus isolated from children in Bangui, Central African Republic. J Clin Microbiol (1988) 1.54
Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet (1999) 1.51
Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients. Transplantation (2000) 1.48
Cargo can modulate COPII vesicle formation from the endoplasmic reticulum. J Biol Chem (1999) 1.47
An outbreak of rotavirus diarrhea among a nonimmune, isolated South American Indian community. Am J Epidemiol (1981) 1.43
HCV and PCR negativity. Lancet (1992) 1.43
Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine (1999) 1.43
Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA. J Virol Methods (2001) 1.43
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. J Hepatol (2001) 1.42
Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother (1999) 1.41
Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol (2001) 1.40
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS (2007) 1.40
HIV and hepatitis C coinfection within the CAESAR study. HIV Med (2004) 1.39
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med (2009) 1.38
Idiopathic CD4+ T-lymphocytopenia--an analysis of five patients with unexplained opportunistic infections. N Engl J Med (1993) 1.38
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS (2001) 1.35
Epidemiological survey of human rotavirus serotypes and electropherotypes in young children admitted to two children's hospitals in northeast London from 1984 to 1990. J Clin Microbiol (1991) 1.34
The influence of divalent cations on the stability of human rotavirus. Arch Virol (1981) 1.28
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS (1999) 1.26
Epidemiology of rotavirus subgroups and serotypes in Belem, Brazil: a three-year study. Ann Inst Pasteur Virol (1989) 1.25
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Med (2010) 1.24
Detection of drug resistance associated mutations in HIV primary infection within the UK. AIDS (2000) 1.24
Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J Acquir Immune Defic Syndr (1999) 1.23
Molecular epidemiology of human rotaviruses. Analysis of outbreaks of acute gastroenteritis in Glasgow and the west of Scotland 1981/82 and 1982/83. J Hyg (Lond) (1984) 1.22
Itraconazole cyclodextrin solution--effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother (1994) 1.22
The reliability of serological tests for the diagnosis of genital herpes: a critique. Pathology (1993) 1.20
Investigation of vesicular rashes for HSV and VZV by PCR. J Med Virol (1998) 1.20
Evaluation of sperm washing as a potential method of reducing HIV transmission in HIV-discordant couples wishing to have children. AIDS (1999) 1.18
Interaction of hepatitis B and hepatitis C infection in haemophilia. Br J Haematol (1993) 1.17
High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol (1999) 1.17
Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol (1998) 1.16
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS (1996) 1.16
Prevalence of antibody to group B (atypical) rotavirus in humans and animals. J Clin Microbiol (1987) 1.15
Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother (2001) 1.14
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med (2009) 1.14
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS (2000) 1.14
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther (2001) 1.14
Evaluation of a new enzyme-linked immunosorbent assay test for rotavirus antigen in faeces. J Clin Pathol (1981) 1.13
Mild hantaviral disease caused by sin Nombre virus in a four-year-old child. Pediatr Infect Dis J (1995) 1.13
Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Res Hum Retroviruses (1994) 1.12
Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child (1990) 1.12
HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med (2007) 1.11
Improving the care of patients with genital herpes. BMJ (2000) 1.11
Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender. HIV Med (2007) 1.10
Hepatitis C in blood donors. Lancet (1993) 1.10
Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Res Hum Retroviruses (2000) 1.09
Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation (1993) 1.09